Advertisement

Platelet transfusion: when, how and how much?

  • V. De Angelis

Abstract

The use of platelets in therapy has become widespread in recent decades. The treatment of haematological and nonhaematological malignancies, bone marrow transplantation procedures and cardiac surgery are responsible for the vast majority of platelet transfusions. However, transfusion of platelets is associated with different post-transfusion reactions: infections due to bacterial contamination are the most frequent side effects of platelet transfusion, but, although less frequent, alloimmunisation, febrile nonhaemolytic reactions, viral infections and transfusion-associated lung injury (TRALI) are also detected by the network of haemovigilance [1]. Finally, platelet concentrates are very costly blood components, and blood and blood components are becoming increasingly scarce in Europe.

Keywords

Platelet Count Thrombotic Thrombocytopenic Purpura Platelet Transfusion Platelet Concentrate Platelet Recovery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wilkinson J, Wilkinson C (2001) Administration of blood transfusions to adults in general hospital settings: a review of the literature. J Clin Nurs 10: 161–170PubMedCrossRefGoogle Scholar
  2. 2.
    Murphy S, Heaton WA, Rebulla P (1996) Platelet production in the Old World — and the New. Transfusion 36: 751–754PubMedCrossRefGoogle Scholar
  3. 3.
    Council of Europe (1988) Guide to the preparation, use and quality assurance of blood components, 4th edn.Google Scholar
  4. 4.
    Patel IP, Ambinder E, Holland JF et al (1978) In vivo and in vitro comparison of single donor platelets and multiple-donor pooled platelets transfusions in leukemic patients. Transfusion 18: 116–119PubMedCrossRefGoogle Scholar
  5. 5.
    Turner VS, Hawker RJ, Mitchell SG et al (1994) Paired in vivo and in vitro comparison of apheresis and recovered platelet concentrates stored for five days. J Clin Apheresis 9: 189–194PubMedCrossRefGoogle Scholar
  6. 6.
    Corbin F (2002) Pathogen inactivation of blood colmponents: current status and introduction of an approach using riboflavin as a photosensitizer. Int J Hematol 76 (Suppl 2): 253–257PubMedCrossRefGoogle Scholar
  7. 7.
    Schiffer CA, Anderson KC, Bennet CL (2001) Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society for Clinical Oncology. J Clin Oncol 19: 1519–1538PubMedGoogle Scholar
  8. 8.
    Mollison PL, Engelfriet CP, Contreras M (1993) Blood transfusion in clinical medicine, 9th edn. Blackwell Scientific Publications, OxfordGoogle Scholar
  9. 9.
    LoScalzo J, Scheffer AI (1998) Thrombosis and hemorrhage. Williams Wilkins, BaltimoreGoogle Scholar
  10. 10.
    Lemmer JH Jr, Metzdorff MT, Krause AH Jr et al (2000) Emergency coronary artery bypass graft surgery in abciximab-treated patients. Ann Thorac Surg 69: 90–95PubMedCrossRefGoogle Scholar
  11. 11.
    National Institutes of Health (1987) Consensus Conference: Platelet transfusion therapy.Transfus Med Rev 1: 195–200Google Scholar
  12. 12.
    Howard SC, Gajjr A, Ribeiro RC et al (2000) Safety of lumbar puncture in children with acute lymphoblastic leukemia and thrombocytopenia. JAMA 284: 2222–2224PubMedCrossRefGoogle Scholar
  13. 13.
    Practice guidelines for blood component therapy. A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy (1996) Anesthesiology 84: 732–745CrossRefGoogle Scholar
  14. 14.
    Norfolk DR, Ancliffe PJ, Contreras M et al (1998) Consensus Conference on platelet transfusion. Royal College of Physicians of Edinburgh. Br J Haematol 101: 609–617Google Scholar
  15. 15.
    Heatn WAL, Rebulla P, Pappalettera M et al (1997) A comparative analysis of different methods for routine blood components preparation. Transfus Med Rev 11: 116–129CrossRefGoogle Scholar
  16. 16.
    Lee D, Contreras M, Robson SC et al (1999) Recommendations for the use of anti-D immunogloblin for Rh prophylaxis. Transfus Med Rev 9: 93–97CrossRefGoogle Scholar
  17. 17.
    NIH Consensus Conference on platelet transfusion (1987) Transfus Med Rev 3: 195–217Google Scholar
  18. 18.
    Murphy MF, Brozovic B, Murphy W et al (1992) Guidelines for platelet transfusions. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force. Transfus Med 2: 311–318PubMedCrossRefGoogle Scholar
  19. 19.
    Council and Scientific Advisory Board of the German Medical Association (1995) Guidelines for therapy with blood components and plasma derivatives. Deutscher Ärtze-VerlagGoogle Scholar
  20. 20.
    Roy AJ, Jaffe N, Djerassi 1 (1973) Prophylactic platelet transfusions in children with acute leukemia: a dose response study. Transfusion 13: 283–290PubMedCrossRefGoogle Scholar
  21. 21.
    Norol F, Bierling P, Roudot-Thoraval F et al (1998) Platelet transfusion: a dose-response study. Blood 92: 1448–1453PubMedGoogle Scholar
  22. 22.
    Ackerman SJ, Klumpp TR, Guzman GI et al (2000) Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial. Transfusion 40: 1457–1462PubMedCrossRefGoogle Scholar
  23. 23.
    Royal College of Physicians of Edinburgh (1998) Consensus Conference on Platelet Transfusion. Transfus Med 8: 149–151CrossRefGoogle Scholar
  24. 24.
    Davis KB, Slichter SJ, Corash L (1999) Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion 39: 586–592PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 2004

Authors and Affiliations

  • V. De Angelis

There are no affiliations available

Personalised recommendations